208 results on '"Maurer, Marcus"'
Search Results
2. Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels
3. The European Network for IgE-Mediated Autoimmunity and Autoallergy (ENIGMA) initiative
4. Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabilization
5. A Patient Charter for Chronic Urticaria
6. Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
7. Emerging Therapeutics in Chronic Urticaria
8. The Definition, Classification, and History of Urticaria
9. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
10. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases
11. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
12. Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry
13. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
14. Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
15. A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
16. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria Are Underused in Clinical Practice
17. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study
18. BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria
19. Comorbid Inducible Urticaria Is Linked to Non-Autoimmune Chronic Spontaneous Urticaria: CURE Insights
20. Green Roof Gardens – Selecting Allergy-Friendly Vegetation: A Global Allergy and Asthma Excellence Network (GA²LEN) Position Paper
21. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
22. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
23. Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria
24. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study
25. The socio‐economic burden of H1‐antihistamine‐refractory chronic spontaneous urticaria in Germany
26. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center
27. Usage prevalence of angioedema patient-reported outcome measures: results from the UCARE and ACARE PROMUSE study
28. Die Mastzelle im Fokus: gestern, heute, morgen
29. Altered Sweat Composition Due to Changes in Tight Junction Expression of Sweat Glands in Cholinergic Urticaria Patients
30. The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)
31. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)
32. Non-Skin-Related Symptoms are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results from CURE
33. An algorithm for the diagnosis and treatment of chronic inducible urticaria, 2024 update.
34. Disease modification in chronic spontaneous urticaria.
35. In chronic spontaneous urticaria, increased Galectin‐9 expression on basophils and eosinophils is linked to high disease activity, endotype‐specific markers, and response to omalizumab treatment.
36. Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment.
37. CD4+CCR5+ T cells and CCL3+ mast cells are increased in the skin of patients with chronic spontaneous urticaria.
38. Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.
39. Recurrent Angio‐Oedema without Weals
40. Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in Germany
41. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study
42. MASK-air®: An OECD (Organisation for Economic Coordination and Development) Best Practice for Public Health on integrated care for chronic diseases.
43. Monitoring recurrent angioedema: Findings from the Turkish angioedema control test validation study
44. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial
45. Enhancing Angioedema Patient Care: Unveiling Underutilization and Barriers in the Implementation of Patient-Reported Outcome Measurements
46. A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU study
47. Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial
48. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study
49. Actual real-world application of PROMs in Asthma and Rhinitis as advised by guidelines: PROMUSE Respiratory Study
50. Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.